Call Us

    What Can I Do When Depression Treatment Isn't Working?

    If you have tried antidepressants and therapy without lasting relief, you are not out of options. Persistent symptoms after adequate treatment may lead a psychiatrist to evaluate other approaches — including FDA-cleared TMS, SAINT® accelerated TMS, SPRAVATO® (esketamine), and ECT. This page explains what each option is, who it may help, and what to ask your psychiatrist.

    If you are having thoughts of harming yourself, call or text 988 (Suicide & Crisis Lifeline, 24/7) or go to your nearest emergency room.

    Key Takeaways

    • Persistent symptoms after two or more adequate antidepressant trials may indicate treatment-resistant depression.
    • An adequate trial means a therapeutic dose for 6 to 8 weeks — an incomplete trial is not a failed trial.
    • TMS and SAINT® are FDA-cleared for adults whose depression has not improved on antidepressants.
    • SPRAVATO® (esketamine) is FDA-approved for treatment-resistant depression.
    • Fast does not mean best for everyone — a psychiatric evaluation guides the choice.

    When Medication Hasn't Worked

    If one or more antidepressants have not produced satisfactory improvement, a psychiatrist first confirms the trials were adequate — therapeutic dose, 6 to 8 weeks. Options include switching to a different medication class, adding an augmenting medication, or moving to a non-medication treatment.

    When Therapy Hasn't Worked

    If psychotherapy has not produced adequate improvement, consider whether the type, intensity, or frequency was sufficient. CBT, behavioral activation, and interpersonal therapy have the strongest evidence. Therapy is often combined with medication or brain stimulation treatments — it does not have to be an either/or choice.

    When Medication and Therapy Haven't Worked

    After adequate medication and therapy without satisfactory improvement, a psychiatrist may diagnose treatment-resistant depression and recommend a treatment that works through a different mechanism.

    Treatment Options at a Glance

    TreatmentTypeTimelineFDA Status
    Conventional TMSNon-invasive brain stimulation~6 weeks (30–36 sessions)FDA-cleared
    SAINT® TMSAccelerated, fMRI-guided TMS5 days (50 sessions)FDA-cleared
    SPRAVATO®Esketamine nasal sprayTwice weekly → weekly → monthlyFDA-approved
    ECTElectrical stimulation under anesthesia6–12 sessions over 3–6 weeksEstablished treatment
    Medication augmentationAdding a second medication6–8 weeks to assessOff-label (varies)

    Individual results vary. No outcome is guaranteed. Eligibility is determined by a qualified healthcare provider.

    Questions to Discuss With Your Psychiatrist

    • Were my medication trials truly adequate — therapeutic dose for 6 to 8 weeks?
    • Could my diagnosis be different (e.g., bipolar depression, a medical condition)?
    • Am I a candidate for TMS or SAINT®?
    • What does my insurance cover, and what will it cost?
    • How quickly can I start treatment?
    • What is the plan if the first treatment doesn't work?
    • What maintenance or follow-up is recommended after treatment?

    Frequently Asked Questions

    What does it mean when depression treatment isn't working?

    Persistent depressive symptoms after adequate treatment — typically two or more antidepressant trials at therapeutic doses for 6 to 8 weeks, plus psychotherapy — may indicate treatment-resistant depression. This does not mean your depression cannot be treated. It means the treatments tried so far were not the right fit. A psychiatrist can confirm whether your trials were adequate and recommend next steps.

    What should I do if my antidepressant and therapy aren't working?

    Ask a psychiatrist to review your full treatment history, confirm whether each medication trial was adequate (therapeutic dose, 6 to 8 weeks), and screen for conditions that can mimic resistance — bipolar disorder, thyroid conditions, substance use. Then discuss treatments you have not yet tried: TMS, SAINT®, SPRAVATO®, medication augmentation, or ECT for severe cases.

    Is there hope after multiple depression treatments fail?

    Yes. Roughly one-third of people do not reach remission after two treatment steps, but many find relief with treatments that work through different mechanisms. TMS and SAINT® use magnetic brain stimulation rather than medication. SPRAVATO® works through the NMDA receptor system. If you are having thoughts of self-harm, call or text 988 now.

    Can TMS help when medication hasn't worked?

    Yes. TMS is FDA-cleared specifically for adults with major depressive disorder who have not improved adequately on antidepressant medication. A real-world study of 307 patients reported about 58% response and 37% remission. TMS does not help everyone, and individual results vary.

    What is the fastest treatment for treatment-resistant depression?

    SAINT® accelerated TMS delivers 50 sessions in 5 consecutive days and is the fastest FDA-cleared course. Average time to remission in the open-label study was 2.6 days. SPRAVATO® (esketamine) can also produce improvement within hours to days. ECT is rapid for severe depression but requires anesthesia. Fast does not mean best for everyone.

    Medically reviewed by Daniel Pietras, MD. Last updated November 3, 2026.

    Not sure what to try next?

    A free consultation with our clinical team can help you understand your options and whether TMS, SAINT®, or SPRAVATO® may be appropriate for you.

    Safety information: SAINT® is not for everyone. It is contraindicated for people with non-removable magnetic-sensitive metal in or near the head, certain implanted devices, or increased intracranial pressure. Possible side effects include headache, fatigue, scalp discomfort and anxiety; TMS carries a small risk of seizure and, as with any depression treatment, a risk of worsening depression or suicidal thoughts. If you are in crisis, call or text 988.

    SAINT® is a registered trademark of Stanford University, exclusively licensed to Magnus Medical, Inc. NWCOA is not affiliated with Stanford University.